BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Aging
    • Biosimilars
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Radiopharmaceuticals
    • Science '22 in Review
    • Top Biopharma Trends of 2022
    • Top Med-tech Trends of 2022
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • sign in
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, September 25, 2023
Home » Blogs » BioWorld Perspectives » You’ve come a long way, baby, but still a long way to go

BioWorld Perspectives
BioWorld Perspectives RSS FeedRSS

BioWorld / Oncology

You’ve come a long way, baby, but still a long way to go

May 4, 2015
By Mari Serebrov
No Comments

blog tvecPatients have come a long way to get a say in the drug development and approval process. But there’s still some ground to cover if they’re going to move from the passive subject role to a 50-50 partnership that reminds researchers, drugmakers and regulators that, “Hey, this is all about us!”

While major drugmakers have been hiring senior-level staff to connect and interact with patients and to incorporate the patient perspective into their R&D for a while now, the regulatory field is making slim – albeit positive – advances in that direction.

In the past, patients often testified during the public hearing sessions of advisory committee meetings, urging approval of a new drug and begging for options to treat life-threatening diseases. Too often, their words fell on deaf ears, as the committee members focused on statistical significance and the conduct of a study rather than the real-life outcomes of patients who actually experienced the risks and benefits of the trial drug.

Last week’s joint meeting of the Cellular, Tissue and Gene Therapies and Oncologic Drugs Advisory Committees  was different. At least some of the panelists truly listened to the patient stories. Louis Diehl, a professor at Duke University Medical Center, cited that experience in unequivocally recommending approval of Amgen Inc.’s melanoma immunotherapy talimogene laherparepvec, or T-vec. A few others also referenced the patient testimony in justifying their yes votes.

Before the final vote, another panelist – a melanoma oncologist – invoked patient need when he argued against his colleagues who wanted the indication narrowed to patients with “unresectable” melanoma. Patrick Hwu, an oncology professor at the University of Texas M.D. Anderson Cancer Center, noted the variety of definitions of “resectable” among oncologists in the field. Restricting T-vec to unresectable melanoma lesions would restrict patient access, Hwu said, as both private and public payers could use that restriction to deny coverage of what could be an expensive treatment.

Oncologists shouldn’t be put in a situation of recommending what might be a life-saving treatment to a patient who is out of options, only to find that Medicare or the patient’s insurance won’t cover it because the payer, which hasn’t laid eyes on the patient – doesn’t consider the lesions unresectable.

The next test of how far patients have come in making their voice heard will be at the FDA when it decides whether to approve novel therapies like T-vec. But the ultimate test of the power of the patient voice looms over drug pricing.

Will patients be able to leverage their growing relationship with drugmakers to change the “what-the-market-can-bear” pricing scheme that makes the U.S. drug market one of the costliest, and most innovative, in the world?

And, perhaps more importantly, will Medicare and private payers join researchers, drugmakers and regulators in finally listening to what patients have to say?

You must login or register in order to post a comment.

Report Abusive Comment

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 22, 2023.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for September 22, 2023.
  • Hands holding torn contract

    Quite a fix: Orthofix sacks three top execs

    BioWorld MedTech
    Orthofix Medical Inc. terminated its CEO, chief financial officer and chief legal officer in a move that plunged the stock from $18.63 at Monday’s close to $13.01...
  • Illustration of Alzheimer’s in the brain.

    Study identifies cause of death for Alzheimer’s neurons

    BioWorld
    By creating a new mouse model of Alzheimer’s disease that better recapitulated how the disease plays out in humans, investigators at KU Leuven have gained new...
  • 3D illustration of cancer in crosshairs

    Dato data lack means upside for Gilead; Padcev 'must-win' does win

    BioWorld
    Upbeat phase III findings outweighed less encouraging late-stage trial news, as big pharma provided a mixed bag of cancer findings – with one data batch to form...
BioFuture ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing